David. P. Southwell has been named president and chief executive officer of Inotek Pharmaceuticals, Inc., and will also join the board of directors. Mr. Southwell has more than 20 years of experience in pharma and biopharma including financings, mergers and acquisitions, and general corporate leadership.
 
Prior to joining the company, he served as executive vice president and chief financial officer of Human Genome Sciences (acquired by GlaxoSmithKline in 2012). Before joining the management team of Human Genome Sciences, he served on the company’s board of directors. Previously, Mr. Southwell was executive vice president and chief financial officer of Sepracor Inc., a position he held for 14 years.
 
“I am excited to be joining Inotek at this time of significant upcoming value inflection points,” said Mr. Southwell. “The company’s lead product, trabodenoson for the treatment of glaucoma, is poised to move into Phase III trials later this year. To date, trabodensoson has shown an excellent safety and efficacy profile in the clinic and is a promising candidate for glaucoma patients. I’m looking forward to joining a leadership team that I have successfully worked with in the past so that we may advance trabodenoson through the clinic and toward marketing approval.”